37.48

2.47% 0.905

Urogen Pharma Ltd (URGN)

Overview News Price History Option Chain Financials Discussions Forecast

Urogen Pharma Ltd stock is traded at $37.48, with a volume of 115.86K. It is up +2.47% in the last 24 hours and down -10.19% over the past month. UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Previous Close:

$36.58

Open:

$37.04

24h Volume:

115.86K

Relative Volume:

0.10

Market Cap:

$1.83B

Revenue:

$140.49M

Net Income/Loss:

$-153.49M

P/E Ratio:

-13.61

EPS:

-2.7551

Net Cash Flow:

$-175.90M

1W Performance:

+1.37%

1M Performance:

-10.19%

6M Performance:

+74.27%

1Y Performance:

+116.80%

1-Day Range:

$37.04

$38.37

1-Week Range:

$36.20

$39.09

52-Week Range:

$16.27

$50.81

Urogen Pharma Ltd Stock (URGN) Company Profile

Name

Urogen Pharma Ltd

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

972 9 770 7601

Address

9 HA'TA'ASIYA ST, RA'ANANA

Employee

291

Twitter

@UroGenPharma

Next Earnings Date

2026-11-05

Latest SEC Filings

URGN's Discussions on Twitter

Compare URGN vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
URGN Urogen Pharma Ltd	37.48	1.83B	140.49M	-153.49M	-175.90M	-2.7551
VRTX Vertex Pharmaceuticals Inc	510.44	129.38B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	238.83	95.35B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	805.77	82.96B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	850.36	53.48B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	370.46	41.91B	5.76B	514.49M	1.10B	4.4813

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-11-26	Resumed	Ladenburg Thalmann	Buy
Apr-10-26	Initiated	Jefferies	Buy
Aug-19-25	Initiated	Piper Sandler	Overweight
Jun-16-25	Upgrade	H.C. Wainwright	Neutral → Buy
May-22-25	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-16-25	Initiated	Scotiabank	Sector Outperform
Feb-19-25	Resumed	Ladenburg Thalmann	Buy
Aug-22-24	Initiated	Guggenheim	Buy
Feb-08-23	Downgrade	Jefferies	Buy → Hold
Apr-27-22	Initiated	Berenberg	Buy
Apr-16-20	Reiterated	H.C. Wainwright	Buy
Apr-13-20	Reiterated	H.C. Wainwright	Buy
Jan-09-20	Initiated	National Securities	Neutral
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy
Nov-15-17	Reiterated	Oppenheimer	Outperform
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

View All

Urogen Pharma Ltd Stock (URGN) Latest News

Oct 13, 2026

UroGen Pharma: An Emerging GARP Stock - Seeking Alpha

Oct 13, 2026

Oct 09, 2026

UroGen Pharma CFO Chris Degnan sells $80,791 in shares By Investing.com - Investing.com Nigeria

Oct 09, 2026

UroGen Pharma CFO Chris Degnan sells $80,791 in shares By Investing.com - Investing.com South Africa

Oct 09, 2026

UroGen Pharma Officer Christopher Degnan Files Rule 144 to Sell 2,202 Shares for Tax Withholding - Kalkine Media

Oct 09, 2026

To cover equity-award taxes, UroGen Pharma (URGN) officer proposes selling 2,202 shares. - Stock Titan

Oct 09, 2026

Form 4 Urogen Pharma Ltd For: 9 October By Investing.com - Investing.com Nigeria

Oct 09, 2026

Sep 30, 2026

Here's Why You Should Add URGN Stock to Your Portfolio Now - Zacks Investment Research

Sep 30, 2026

Sep 23, 2026